Apogem Capital’s ADC Therapeutics ADCT Stock Holding History

Apogem Capital’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,405	Closed	-$84K	–	3
2022 Q3	$84K	Buy	+17,405	New	+$126K	0.08%	132

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Apogem Capital's ADCT Position: Q4 2022 in Review

Apogem Capital sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 17,405 shares — an estimated $84K sold.

Apogem Capital first reported a position in ADCT in Q3 2022 and held it in 1 quarter. The position peaked at $84K in Q3 2022. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

Apogem Capital reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
Apogem Capital sold 17,405 ADC Therapeutics shares in Q4 2022, an estimated $84K.
Apogem Capital first reported a position in ADC Therapeutics in Q3 2022 and held it in 1 quarter.
Apogem Capital's ADC Therapeutics position peaked at $84K in Q3 2022.
60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.